Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open Label, Phase I Trial of the MEK Inhibitor AS703026 Given Orally to Subjects With Solid Tumours

Next Previous
Trial Profile

A Multicenter, Open Label, Phase I Trial of the MEK Inhibitor AS703026 Given Orally to Subjects With Solid Tumours

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimasertib (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Mesothelioma; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Merck KGaA

Most Recent Events

  • 19 Nov 2020 Results (n=89) assessing efficacy, safety, and pharmacodynamics of pimasertib at pharmacologically active doses in patients with melanoma, published in the Targeted Oncology
  • 10 Nov 2020 After determination of MTD and/or MAD for Regimen1/Regimen2, and critical evaluation of need for a washout period between doses based on safety, PK and PD outcomes, clinical trial protocol was amended to allow for testing of continuous qd and continuous bid dosing in patients with Melanoma (since preliminary evidence of antitumor activity had been observed in melanoma patients).
  • 10 Nov 2020 Results published in the Targeted Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top